Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ethinylestradiol + gestodene (Morningside Healthcare)
- Development stage
- Unknown
- Lead developer
- Morningside Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Akizza is a combined oral contraceptive (COC) pill containing the synthetic estrogen ethinylestradiol and the third-generation progestin gestodene. It is indicated for the prevention of pregnancy (oral contraception). The contraceptive effect of Akizza is achieved through multiple mechanisms, primarily the inhibition of ovulation by suppressing the mid-cycle gonadotropin surge, thickening of the cervical mucus to prevent sperm penetration, and altering the endometrium to reduce the likelihood of implantation. Originally developed by Morningside Healthcare, Akizza became part of the Aspire Pharma portfolio following Aspire's acquisition of Morningside in October 2022.
- Brand names
- AkizzaFemodeneFemodene EDFemodetteGyneraHarmonetKatyaLindynetteLogestMelianeMillinetteMinesseMinuletMirelleSunyaTriadene
- Other names
- ethinylestradiol + gestodeneethinylestradiol/gestodenegestodene + ethinylestradiolgestodene/ethinylestradiol
02
Targets
PR (Progesterone receptor)ESR1 (ERα)GPER1 (G protein-coupled estrogen receptor 1)GR (Glucocorticoid receptor)ESR2 (ERβ)AR (Adrenergic receptors)
Beyond the preview
Go deeper on ethinylestradiol + gestodene (Morningside Healthcare).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ethinylestradiol + gestodene (Morningside Healthcare).